Meckler Jeffrey A 4

What Happened Jeffrey A. Meckler, a director of Travere Therapeutics, received equity awards on May 19, 2026. The Form 4 shows two awards (transaction code A): 4,000 shares of common stock acquired at $0.00 and 12,000 derivative shares acquired at $0.00, for a total of 16,000 shares granted as part of the company's director compensation program. These were compensation awards (not purchases or sales).

Key Details

• Transaction date: 2026-05-19; Form 4 filed 2026-05-21 (appears timely).
• Reported acquisition price: $0.00 for both grants (compensation awards).
• Shares granted: 4,000 shares (direct) + 12,000 derivative shares = 16,000 total.
• Shares owned after the transaction: not specified in the filing.
• Footnotes: F1 — automatic equity grant under the Issuer's 2018 Equity Incentive Plan for non‑employee directors; F2 — the equity award vests over a one‑year period.
• Transaction code: A = Award/Grant.

Context These awards are standard non‑employee director equity compensation and should be viewed as compensation rather than a market purchase or sale. The 12,000 derivative shares are an equity award that converts to common stock upon vesting (per the filing); vesting is over one year. Such grants are routine for boards and do not, by themselves, indicate insider buying or selling sentiment.